AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27382274 — intervention group
Group type: EXPERIMENTAL
Intervention: POC PCT-guided intervention (n=62)
Number of subjects: 120
Study 27382274 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=58)
Number of subjects: 120
Study 27382274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 23982564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection (IACI) of 80 mg of methylprednisolone acetate (MPA)
Number of subjects: 20
Study 23982564 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection (IAI) of 6 ml (60 mg) of sodium hyaluronate (control group)
Number of subjects: 20
Study 23427384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar tender point deep tissue massage plus lumbar traction
Number of subjects: 64
Study 23427384 — intervention group
Group type: COMPARATOR
Intervention: Lumbar traction alone
Number of subjects: 64
Study 19293690 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational technique (n = 80)
Number of subjects: 160
Study 19293690 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (n = 80)
Number of subjects: 160
Study 17219379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular polyestradiol phosphate (PEP) 240 mg/month
Number of subjects: 444
Study 17219379 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy (OE)
Number of subjects: 444
Study 17219379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular polyestradiol phosphate (PEP)
Number of subjects: 444
Study 15857105 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream applied twice daily for 4 weeks
Number of subjects: 20
Study 15857105 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study 15094146 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater recording without water-resistant adhesive taping (PW)
Number of subjects: 10
Study 15094146 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater recording with moving water and without water-resistant adhesive taping (PWM)
Number of subjects: 10
Study 15094146 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater recording with water-resistant adhesive taping (T)
Number of subjects: 10
Study 15094146 — intervention group
Group type: COMPARATOR
Intervention: Dry condition (D)
Number of subjects: 10
Study 11213071 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a, 3 mU daily for 12 months
Number of subjects: 12
Study 11213071 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study 9692058 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 68
Study 9692058 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 68
Study 7939127 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom diaries over a 4-month period
Number of subjects: 27
Study 7939127 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day diary design
Number of subjects: 27
Study 7939127 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability assessment
Number of subjects: 27
Study 7939127 — intervention group
Group type: EXPERIMENTAL
Intervention: Training period prior to trial
Number of subjects: 27
Study 7939127 — intervention group
Group type: COMPARATOR
Intervention: Treatment with stimulant medications
Number of subjects: 27
Study 7939127 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily distribution of cataplexy attacks
Number of subjects: 27
Study 7939127 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional events or sleepiness
Number of subjects: 27
Study 7939127 — intervention group
Group type: EXPERIMENTAL
Intervention: Precataplectic feeling or aura
Number of subjects: 27
Study 2463720 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprafenone 450 mg/day
Number of subjects: 10
Study 2463720 — intervention group
Group type: COMPARATOR
Intervention: Propafenone 450 mg/day
Number of subjects: 10
Study 29602883 — intervention group
Group type: EXPERIMENTAL
Intervention: Danegaptide high dose
Number of subjects: 585
Study 29602883 — intervention group
Group type: EXPERIMENTAL
Intervention: Danegaptide low dose
Number of subjects: 585
Study 29602883 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 585
Study 28110287 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose aspirin (100 mg)
Number of subjects: 16703
Study 28110287 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 16703
Study 26817346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolytic drugs
Number of subjects: 499
Study 26817346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 499
Study 23260616 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer teaching in addition to faculty instruction
Number of subjects: 230
Study 23260616 — intervention group
Group type: COMPARATOR
Intervention: Faculty instruction only
Number of subjects: 230
Study 21700934 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC1779
Number of subjects: 36
Study 21700934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19005298 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP)
Number of subjects: 153
Study 19005298 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 153
Study 19005298 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Treatment (Control)
Number of subjects: 153
Study 17124449 — intervention group
Group type: COMPARATOR
Intervention: Intra-focal pinning (group K) using one or two dorsal pins and one lateral pin
Number of subjects: 85
Study 17124449 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-focal pinning (group KM) using one or two intra-focal pins and one lateral transfocal pin
Number of subjects: 85
Study 17124449 — intervention group
Group type: COMPARATOR
Intervention: Intra-focal pinning (group K) at day 45 postoperative
Number of subjects: 85
Study 17124449 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-focal pinning (group KM) at day 45 postoperative
Number of subjects: 85
Study 15276957 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for neuropsychiatric symptoms of TBI
Number of subjects: 0
Study 15276957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10845171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercede (oxidized regenerated cellulose adhesion barrier)
Number of subjects: 38
Study 10845171 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant)
Number of subjects: 38
Study 8694318 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory stimulation with 60 electric pulses (20 mA, 0.2 ms) to the tips of the fingers for 10 min, followed by continued stimulation for 20 min after anesthetic injection.
Number of subjects: 10
Study 8694318 — intervention group
Group type: COMPARATOR
Intervention: Somatosensory stimulation applied to the anesthetized finger.
Number of subjects: 10
Study 1311661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion (20% w/v, 1 ml/min for 120 min) during hyperinsulinaemic euglycaemic clamp (100 m-units h-1 kg-1)
Number of subjects: 7
Study 1311661 — intervention group
Group type: COMPARATOR
Intervention: Control (0.154 mol/l NaCl infusion)
Number of subjects: 7
Study 2984913 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 20 mg twice daily)
Number of subjects: 32
Study 2984913 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 to 100 mg thrice daily)
Number of subjects: 32
Study 2984913 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor placebos
Number of subjects: 32
Study 2984913 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-methyldopa (250 to 500 mg twice daily)
Number of subjects: 32
Study 30471802 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong intervention (audit, feedback, collaborative work with a hospital geriatrician)
Number of subjects: 3722
Study 30471802 — intervention group
Group type: COMPARATOR
Intervention: Light intervention group (audit and feedback only)
Number of subjects: 3722
Study 30471802 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong intervention
Number of subjects: 3722
Study 26786577 — intervention group
Group type: EXPERIMENTAL
Intervention: CANA100/MET
Number of subjects: 1186
Study 26786577 — intervention group
Group type: EXPERIMENTAL
Intervention: CANA300/MET
Number of subjects: 1186
Study 26786577 — intervention group
Group type: EXPERIMENTAL
Intervention: CANA100
Number of subjects: 1186
Study 26786577 — intervention group
Group type: EXPERIMENTAL
Intervention: CANA300
Number of subjects: 1186
Study 26786577 — intervention group
Group type: COMPARATOR
Intervention: MET
Number of subjects: 1186
Study 26786577 — intervention group
Group type: EXPERIMENTAL
Intervention: CANA arms
Number of subjects: 1186
Study 24119443 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/oxaliplatin chemotherapy
Number of subjects: 150
Study 21828031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg every 6 h until neutropenia)
Number of subjects: 20
Study 21828031 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (1994‐2002)
Number of subjects: 20
Study 19484628 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (Exelon) at a maximum dose of 12 mg daily for 8 weeks
Number of subjects: 102
Study 19484628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 17252021 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM‐CSF)
Number of subjects: 259
Study 17252021 — intervention group
Group type: COMPARATOR
Intervention: Control (timed‐sequential induction regimen alone)
Number of subjects: 259
Study 17252021 — intervention group
Group type: COMPARATOR
Intervention: Control (timed‐sequential consolidation without GM‐CSF)
Number of subjects: 259
Study 15684231 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extracts (St John's wort)
Number of subjects: 37
Study 15684231 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antidepressants
Number of subjects: 37
Study 15684231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 12230056 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal access surgery (MAS)
Number of subjects: 2195
Study 12230056 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 2195
Study 10086836 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dose of dolasetron mesylate solution
Number of subjects: 18
Study 10086836 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dose of dolasetron mesylate solution
Number of subjects: 18
Study 10086836 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dose of dolasetron mesylate solution
Number of subjects: 18
Study 7733082 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg p.o. b.i.d. for 1 week
Number of subjects: 9
Study 7733082 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 9
Study 1647194 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms kg-1
Number of subjects: 6
Study 1647194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6122327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.05 mg/kg)
Number of subjects: 130
Study 6122327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (1 mg/kg)
Number of subjects: 130
Study 6122327 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (0.14 mg/kg)
Number of subjects: 130
Study 6122327 — intervention group
Group type: EXPERIMENTAL
Intervention: Light premedication
Number of subjects: 130
Study 6122327 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnesic premedication
Number of subjects: 130
Study 6122327 — intervention group
Group type: COMPARATOR
Intervention: Amnesic premedication (received by patients expecting light premedication)
Number of subjects: 130
Study 6122327 — intervention group
Group type: COMPARATOR
Intervention: Light premedication (received by patients expecting amnesic premedication)
Number of subjects: 130
Study 6368765 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (Vancomycin and Gentamicin administered systemically, Streptomycin in irrigating solution)
Number of subjects: 0
Study 6368765 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 0
Study 30544795 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina maxima (4.5 g for 12 weeks)
Number of subjects: 16
Study 30544795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27804270 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 2684
Study 27804270 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 2684
Study 27804270 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing training
Number of subjects: 2684
Study 27804270 — intervention group
Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 2684
Study 25198224 — intervention group
Group type: COMPARATOR
Intervention: Floor exercises
Number of subjects: 39
Study 25198224 — intervention group
Group type: COMPARATOR
Intervention: High Magnitude Mechanical Stimulation (HMMS)
Number of subjects: 39
Study 25198224 — intervention group
Group type: EXPERIMENTAL
Intervention: HMMS
Number of subjects: 39
Study 25198224 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 39
Study 22436536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) administration
Number of subjects: 10
Study 22436536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20381660 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of NSAIDs
Number of subjects: 2954
Study 20381660 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of NSAIDs
Number of subjects: 2954
Study 20381660 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs in patients with previous ischemic heart disease
Number of subjects: 2954
Study 19010617 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 2mg/day (ERT)
Number of subjects: 43
Study 19010617 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 2mg/day plus medroxyprogesterone acetate 5mg/day (HRT)
Number of subjects: 43
Study 19010617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 15831684 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of at least one folate fortified food
Number of subjects: 468
Study 15831684 — intervention group
Group type: COMPARATOR
Intervention: Subjects who consumed at least one folate fortified food
Number of subjects: 468
Study 12167942 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sodium bicarbonate oral composition
Number of subjects: 32
Study 12167942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9012623 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol 100 micrograms via Turbuhaler (2 x 50 micrograms)
Number of subjects: 37
Study 9012623 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 200 micrograms via pMDI (2 x 100 micrograms)
Number of subjects: 37
Study 9012623 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol 100 micrograms via Turbuhaler
Number of subjects: 37
Study 9012623 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 37
Study 7881024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human epidermal growth factor (hEGF) 6 micrograms twice a week
Number of subjects: 173
Study 7881024 — intervention group
Group type: COMPARATOR
Intervention: Cetraxate hydrochloride (CH)
Number of subjects: 173
Study 3203698 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased daily fluid intake (1.51 liters per day)
Number of subjects: 100
Study 3203698 — intervention group
Group type: COMPARATOR
Intervention: Standard daily fluid intake (3.01 liters per day)
Number of subjects: 100
Study 31844950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular steroid with hydrodilatation (distension group)
Number of subjects: 40
Study 31844950 — intervention group
Group type: COMPARATOR
Intervention: Only intra-articular steroid (non-distension group)
Number of subjects: 40
Study 31844950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular steroid with hydrodilatation (distension group) among diabetics
Number of subjects: 40
Study 31844950 — intervention group
Group type: COMPARATOR
Intervention: Only intra-articular steroid (non-distension group) among diabetics
Number of subjects: 40
Study 31844950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular steroid with hydrodilatation (distension group) among diabetic and non-diabetic patients
Number of subjects: 40
Study 31844950 — intervention group
Group type: COMPARATOR
Intervention: Only intra-articular steroid (non-distension group) among diabetic and non-diabetic patients
Number of subjects: 40
Study 31844950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 29650210 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair yoga with spiritual intervention
Number of subjects: 84
Study 29650210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study 26391390 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with orally administered estrogen and medroxyprogesterone acetate
Number of subjects: 88
Study 26391390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 88
Study 26391390 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 88
Study 24684774 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 24684774 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 22928654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (1x108 cfu)
Number of subjects: 160
Study 22928654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 20920040 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine DCR 30 mg
Number of subjects: 74
Study 20920040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 18040272 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 391
Study 18040272 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 391
Study 18040272 — intervention group
Group type: EXPERIMENTAL
Intervention: No progressive disease (no PD) patients
Number of subjects: 391
Study 18040272 — intervention group
Group type: COMPARATOR
Intervention: Progressive disease (PD) patients
Number of subjects: 391
Study 16056126 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal alcohol exposure
Number of subjects: 42
Study 16056126 — intervention group
Group type: COMPARATOR
Intervention: Normally developing individuals
Number of subjects: 42
Study 11991313 — intervention group
Group type: EXPERIMENTAL
Intervention: Upbeat music group
Number of subjects: 45
Study 11991313 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music group
Number of subjects: 45
Study 11991313 — intervention group
Group type: COMPARATOR
Intervention: No music group
Number of subjects: 45
Study 9583546 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 50
Study 9583546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural analgesia (IPA)
Number of subjects: 50
Study 9583546 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study 7651642 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational brochures and tracking system
Number of subjects: 100
Study 7651642 — intervention group
Group type: COMPARATOR
Intervention: Usual contact procedures (Control)
Number of subjects: 100
Study 2668706 — intervention group
Group type: EXPERIMENTAL
Intervention: CIAC Scheme (domiciliary care)
Number of subjects: 60
Study 2668706 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital antenatal care (control)
Number of subjects: 60
Study 1052683 — intervention group
Group type: EXPERIMENTAL
Intervention: Step indentations of the index finger tip via mechanostimulator
Number of subjects: 0
Study 31707940 — intervention group
Group type: EXPERIMENTAL
Intervention: Black vignette
Number of subjects: 422
Study 31707940 — intervention group
Group type: COMPARATOR
Intervention: White vignette
Number of subjects: 422
Study 29933716 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 171
Study 26977623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoten
Number of subjects: 60
Study 26977623 — intervention group
Group type: COMPARATOR
Intervention: Pain relievers (Control)
Number of subjects: 60
Study 24624990 — intervention group
Group type: EXPERIMENTAL
Intervention: school‐led FRIENDS
Number of subjects: 41
Study 24624990 — intervention group
Group type: EXPERIMENTAL
Intervention: health care‐led FRIENDS
Number of subjects: 41
Study 24624990 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 41
Study 22184409 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of ICE (if negative FDG-PET scan) followed by HDT/ASCT
Number of subjects: 0
Study 22184409 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 biweekly doses of gemcitabine, vinorelbine, and liposomal doxorubicin (if positive FDG-PET scan)
Number of subjects: 0
Study 19815600 — intervention group
Group type: COMPARATOR
Intervention: Complementary and alternative medicine (CAM) therapies
Number of subjects: 45
Study 19815600 — intervention group
Group type: COMPARATOR
Intervention: Trials failing to meet validity criteria
Number of subjects: 45
Study 17481702 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Detection System (ODS) used as an adjunct to colposcopy
Number of subjects: 193
Study 17481702 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy alone
Number of subjects: 193
Study 14693671 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 76
Study 14693671 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 76